This invention provides novel 3-amino propanamide selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.
                            这项发明提供了新型的3-
氨基丙酰胺选择性雄激素受体降解剂(
SARD)化合物,以及在治疗前列腺癌、晚期前列腺癌、去势抵抗性前列腺癌、雄激素性脱发或其他高雄激素皮肤疾病、肯尼迪病、肌萎缩侧索硬化症(ALS)和子宫肌瘤中的应用的药物组合物,以及用于减少受试者中雄激素受体全长(AR-FL)包括致病性或耐药突变、AR剪接变体(AR-SV)和AR的致病性多谷
氨酸(polyQ)多态性的
水平的方法。